Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence

Bottom line

• In a randomized, placebo-controlled study of 163 dogs with motion sickness, 15 of 106 given maropitant vomited compared with 69 of 105 given placebo (P less than 0.0001).
• A blinded, placebo-controlled trial in 41 cats with IRIS Stage II or III chronic kidney disease demonstrated a statistically significant decrease in vomiting with oral maropitant treatment (P less than 0.01).
• FDA-approved in dogs for prevention of acute vomiting and vomiting due to motion sickness; widely used off-label in cats.
• Maropitant selectively antagonizes NK1 receptors, blocking substance P at both central and peripheral emetic pathways.
• In the feline CKD trial, vomiting was significantly reduced but appetite scores, body weight, and serum creatinine were not significantly different from placebo over 2 weeks.

Drug facts

• Class: Neurokinin-1 (NK1) receptor antagonist
• Mechanism: Selectively antagonizes NK1 receptors in the emetic center and periphery, blocking the action of substance P; suppresses both peripheral and central (vestibular) emetic stimuli
• Route: Oral tablets (dogs, FDA-labeled); injectable solution (dogs and cats, FDA-labeled for dogs); used off-label orally in cats
• Indication: FDA-approved for prevention of acute vomiting and motion sickness vomiting in dogs 2 months of age and older; off-label antiemetic use in cats is well established
• Approval: FDA-approved (NADA 141-263) — Zoetis; initially approved 2007
• Label contraindications: Per label — dogs younger than 7 weeks; not for use in breeding, pregnant, or lactating animals; avoid or use with caution in animals with hepatic dysfunction
• Label common AEs: Per label — pain or vocalization at subcutaneous injection site; salivation at high oral doses; sedation at supratherapeutic doses

A specific patient on maropitant?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=maropitant-dogs-cats-vomiting

What the evidence shows

Canine motion sickness prevention: Conder et al., 2008

Conder et al. reported a randomized, crossover, placebo-controlled study across 26 veterinary clinics enrolling 163 evaluable dogs with motion sickness during automobile travel. Maropitant was administered orally at approximately 2 hours (Trial 1) or 10 hours (Trial 2) before a 60-minute automobile ride. The primary outcome was incidence of vomiting during the ride. In the pivotal analysis, 15 of 106 maropitant-treated dogs vomited compared with 69 of 105 placebo-treated dogs (P less than 0.0001). An earlier exploratory study of 17 dogs showed 10 of 17 placebo-treated and 3 of 17 maropitant-treated dogs vomited. Reduction in overall recovery-phase behaviors (aimless movement, vocalization, panting) was also observed in the maropitant group.

Feline chronic kidney disease vomiting: Quimby et al., 2015

Quimby et al. enrolled 41 cats with stable IRIS Stage II or III CKD and chronic vomiting attributed to uremia in a blinded, placebo-controlled, randomized trial. Maropitant was administered orally once daily for 2 weeks with owners maintaining daily vomiting and appetite logs. There was a statistically significant decrease in vomiting frequency in maropitant-treated cats (P less than 0.01). However, appetite scores, activity scores, body weight, and serum creatinine did not differ significantly between maropitant and placebo groups over the 2-week period. The authors concluded that maropitant palliates CKD-associated vomiting but does not broadly improve clinical outcomes in the short term.

NK1 receptor mechanism and label support

The DailyMed label for CERENIA (maropitant citrate) Tablets confirms the pharmacological class as a neurokinin-1 receptor antagonist that blocks pharmacological action of substance P in the central nervous system, with approved indication for the prevention of acute vomiting and prevention of vomiting due to motion sickness in dogs. The label lists tablets in 16, 24, 60, and 160 mg scored formulations; per-label dosing should be consulted for current weight-based guidance.

How this fits clinical practice

Maropitant is one of the most versatile antiemetics in small animal medicine. Its dual central and peripheral NK1 blockade makes it effective across a wide range of emetic stimuli — from motion sickness and chemotherapy-induced emesis to postoperative nausea and uraemic vomiting. The Quimby et al. feline CKD trial establishes reasonable evidence for short-term palliation of uraemic vomiting, though clinicians should communicate to clients that appetite and body weight improvements are not reliably observed in the short term.

Injectable maropitant is used perioperatively in dogs and cats to reduce anesthetic-related nausea, though specific perioperative dosing details should be confirmed with current formulary references. Long-term use in cats with CKD is practiced clinically, but controlled long-term data beyond 2 weeks in cats remain limited.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=maropitant-dogs-cats-vomiting

References

1. Conder GA et al. Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs. J Vet Pharmacol Ther. 2008. https://pubmed.ncbi.nlm.nih.gov/19000275/
2. Quimby JM et al. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial. J Feline Med Surg. 2015;17(4):348-353. https://pmc.ncbi.nlm.nih.gov/articles/PMC11104052/
3. DailyMed — Label: CERENIA (maropitant citrate) Tablets. Zoetis. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bc065ce-09d6-4131-a5a0-dca3909e0bc8

Changelog

• 2026-06-06: First published.

Related reads

• Capromorelin Canine Appetite Stimulant
• Mirtazapine Transdermal Cats Appetite